| ASP2151, a novel helicase–primase inhibitor, possesses antiviral activity against varicella–zoster virus and herpes simplex virus types 1 and 2 K Chono, K Katsumata, T Kontani, M Kobayashi, K Sudo, T Yokota, ... Journal of antimicrobial chemotherapy 65 (8), 1733-1741, 2010 | 155 | 2010 |
| Targeted antibody and cytokine cancer immunotherapies through collagen affinity J Ishihara, A Ishihara, K Sasaki, SSY Lee, JM Williford, M Yasui, H Abe, ... Science translational medicine 11 (487), eaau3259, 2019 | 154 | 2019 |
| Targeting inflammatory sites through collagen affinity enhances the therapeutic efficacy of anti-inflammatory antibodies K Katsumata, J Ishihara, A Mansurov, A Ishihara, MM Raczy, E Yuba, ... Science advances 5 (11), eaay1971, 2019 | 55 | 2019 |
| Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes K Katsumata, K Chono, K Sudo, Y Shimizu, T Kontani, H Suzuki Molecules 16 (9), 7210-7223, 2011 | 40 | 2011 |
| Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus K Chono, K Katsumata, H Suzuki, K Shiraki Antiviral research 97 (2), 154-160, 2013 | 37 | 2013 |
| Characterization of virus strains resistant to the herpes virus helicase–primase inhibitor ASP2151 (Amenamevir) K Chono, K Katsumata, T Kontani, K Shiraki, H Suzuki Biochemical Pharmacology 84 (4), 459-467, 2012 | 36 | 2012 |
| ASP2397 Is a Novel Natural Compound That Exhibits Rapid and Potent Fungicidal Activity against Aspergillus Species through a Specific Transporter I Nakamura, K Ohsumi, S Takeda, K Katsumata, S Matsumoto, ... Antimicrobial Agents and Chemotherapy 63 (10), 10.1128/aac. 02689-18, 2019 | 32 | 2019 |
| Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection K Katsumata, K Chono, K Kato, Y Ohtsu, S Takakura, T Kontani, H Suzuki Antimicrobial agents and chemotherapy 57 (3), 1339-1346, 2013 | 31 | 2013 |
| Prolonged residence of an albumin–IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis A Ishihara, J Ishihara, EA Watkins, AC Tremain, M Nguyen, A Solanki, ... Nature Biomedical Engineering 5 (5), 387-398, 2021 | 29 | 2021 |
| Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor K Katsumata, A Weinberg, K Chono, S Takakura, T Kontani, H Suzuki Antimicrobial agents and chemotherapy 56 (7), 3587-3591, 2012 | 22 | 2012 |
| Suppression of rheumatoid arthritis by enhanced lymph node trafficking of engineered interleukin‐10 in murine models E Yuba, E Budina, K Katsumata, A Ishihara, A Mansurov, AT Alpar, ... Arthritis & Rheumatology 73 (5), 769-778, 2021 | 20 | 2021 |
| Conferring extracellular matrix affinity enhances local therapeutic efficacy of anti-TNF-α antibody in a murine model of rheumatoid arthritis K Katsumata, J Ishihara, K Fukunaga, A Ishihara, E Yuba, E Budina, ... Arthritis research & therapy 21, 1-10, 2019 | 16 | 2019 |
| Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection K Katsumata, K Chono, H Suzuki Biochemical Pharmacology 158, 201-206, 2018 | 13 | 2018 |
| Susceptibility of Clostridium species isolated in Japan to fidaxomicin and its major metabolite OP-1118 K Yanagihara, N Akamatsu, J Matsuda, N Kaku, K Katsumata, K Kosai Journal of infection and chemotherapy 24 (6), 492-495, 2018 | 11 | 2018 |
| Antimicrobial activity of fidaxomicin against Clostridium difficile clinical isolates in Aichi area in Japan Y Yamagishi, N Nishiyama, Y Koizumi, Y Matsukawa, H Suematsu, ... Journal of infection and chemotherapy 23 (10), 724-726, 2017 | 7 | 2017 |
| Efficacy of acute oral treatment with ASP2151 or valacyclovir (VACV) against cutaneous infection with herpes simplex virus (HSV) type 1 in mice K Katsumata, K Chono, T Kontani, K Sudo, Y Shimizu, H Suzuki Poster V-1742, Interscience Conference on Antimicrobial Agents and Chemotherapy, 2009 | 5 | 2009 |
| Integrative pharmacokinetic–pharmacodynamic modeling and simulation of amenamevir (ASP2151) for treatment of recurrent genital herpes A Takada, M Katashima, A Kaibara, K Chono, K Katsumata, T Sawamoto, ... Drug Metabolism and Pharmacokinetics 31 (4), 323-332, 2016 | 3 | 2016 |
| Preclinical evaluation of ASP5286, a novel cyclophilin inhibitor with potent anti-HCV activity: 1899 M Sawada, E Tsujii, Y Morishita, M Uchida, K Katsumata, K Maki, ... Hepatology 56, 1078A, 2012 | 3 | 2012 |
| Prolonged residence of an albumin-IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis (Oct, 10.1038/s41551-020-00627-3, 2020) A Ishihara, J Ishihara, EA Watkins, AC Tremain, M Nguyen, A Solanki, ... NATURE BIOMEDICAL ENGINEERING 4 (11), 1117-1117, 2020 | 2 | 2020 |
| Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents JA Hubbell, K Katsumata, A Ishihara, J Ishihara, A Mansurov | 1 | 2020 |
